Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
Cantor Fitzgerald
UBS
Teva
US Department of Justice
Cipla
Express Scripts
Mallinckrodt
Covington

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,475,841

« Back to Dashboard

Summary for Patent: 8,475,841
Title:Controlled release metformin formulations
Abstract: Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.
Inventor(s): Cheng; Xiu Xiu (Weston, FL), Jan; Steve (Coral Spings, FL), Chou; Joseph (Manasses, VA), Chen; Chih-Ming (Taipei, TW)
Assignee: Andrx Labs, LLC (Davie, FL)
Application Number:13/052,154
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form; Device;

Drugs Protected by US Patent 8,475,841

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa ACTOPLUS MET XR metformin hydrochloride; pioglitazone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022024-001 May 12, 2009 RX Yes No ➤ Sign Up ➤ Sign Up ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE ➤ Sign Up
Takeda Pharms Usa ACTOPLUS MET XR metformin hydrochloride; pioglitazone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022024-002 May 12, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE ➤ Sign Up
Andrx Labs Llc FORTAMET metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021574-002 Apr 27, 2004 AB2 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION ➤ Sign Up
Andrx Labs Llc FORTAMET metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021574-001 Apr 27, 2004 AB2 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,475,841

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,099,859 Controlled release oral tablet having a unitary core ➤ Sign Up
6,495,162 Controlled release oral tablet having a unitary core ➤ Sign Up
7,919,116 Controlled release metformin formulations ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,475,841

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2013237689 ➤ Sign Up
Japan 5427677 ➤ Sign Up
Japan 2010159290 ➤ Sign Up
Japan 4557424 ➤ Sign Up
Japan 2002506810 ➤ Sign Up
Hong Kong 1037963 ➤ Sign Up
Spain 2540972 ➤ Sign Up
Spain 2328308 ➤ Sign Up
European Patent Office 2087889 ➤ Sign Up
European Patent Office 1063971 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Farmers Insurance
US Department of Justice
Chubb
McKesson
Mallinckrodt
Johnson and Johnson
Teva
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot